BRPI0820707A2 - Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40 - Google Patents

Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40

Info

Publication number
BRPI0820707A2
BRPI0820707A2 BRPI0820707-0A BRPI0820707A BRPI0820707A2 BR PI0820707 A2 BRPI0820707 A2 BR PI0820707A2 BR PI0820707 A BRPI0820707 A BR PI0820707A BR PI0820707 A2 BRPI0820707 A2 BR PI0820707A2
Authority
BR
Brazil
Prior art keywords
responsiveness
assessing
composition
methods
cell lymphoma
Prior art date
Application number
BRPI0820707-0A
Other languages
English (en)
Inventor
David Dornan
Bruce Burington
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0820707A2 publication Critical patent/BRPI0820707A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0820707-0A 2007-11-07 2008-11-07 Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40 BRPI0820707A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98627707P 2007-11-07 2007-11-07
PCT/US2008/082920 WO2009062125A1 (en) 2007-11-07 2008-11-07 Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies

Publications (1)

Publication Number Publication Date
BRPI0820707A2 true BRPI0820707A2 (pt) 2015-06-16

Family

ID=40377361

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820707-0A BRPI0820707A2 (pt) 2007-11-07 2008-11-07 Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40

Country Status (11)

Country Link
US (1) US9068230B2 (pt)
EP (1) EP2222875B1 (pt)
JP (2) JP5730576B2 (pt)
KR (1) KR101620642B1 (pt)
CN (1) CN101910414B (pt)
AU (1) AU2008323701B2 (pt)
BR (1) BRPI0820707A2 (pt)
CA (1) CA2704499C (pt)
IL (1) IL205391A (pt)
MX (1) MX2010005080A (pt)
WO (1) WO2009062125A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009131365A2 (ko) * 2008-04-21 2009-10-29 한국생명공학연구원 위암 진단 마커로서의 ｃst1, ｄcc1, ifitm1 또는 ｍelk
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
WO2010053587A2 (en) 2008-11-07 2010-05-14 Mlc Dx Incorporated Methods of monitoring conditions by sequence analysis
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
PL2387627T3 (pl) 2009-01-15 2016-10-31 Profilowanie odporności adaptacyjnej i wytwarzanie przeciwciał monoklonalnych
WO2010121231A1 (en) * 2009-04-18 2010-10-21 Genentech, Inc. Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
KR20120044941A (ko) 2009-06-25 2012-05-08 프레드 헛친슨 켄서 리서치 센터 적응 면역의 측정방법
US20130095473A1 (en) * 2010-06-14 2013-04-18 Qiagen Gmbh Method for determination of target cells or tissue for extraction of biomolecules from fixed biological samples
BR112013021725A2 (pt) 2011-02-28 2016-11-01 Genentech Inc marcadores biológicos e métodos para prever resposta aos antagonistas de células b
US8592156B2 (en) * 2011-08-08 2013-11-26 Roche Molecular Systems, Inc. Predicting response to anti-CD20 therapy in DLBCL patients
WO2013036459A2 (en) * 2011-09-09 2013-03-14 Sequenta, Inc. Sequence-based measures of immune response
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
CA2853088C (en) 2011-10-21 2018-03-13 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
EP3904536B1 (en) 2011-12-09 2025-10-29 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
US10077478B2 (en) 2012-03-05 2018-09-18 Adaptive Biotechnologies Corp. Determining paired immune receptor chains from frequency matched subunits
KR101621643B1 (ko) 2012-05-08 2016-05-16 어댑티브 바이오테크놀로지스 코포레이션 다중 pcr 반응에서 증폭 바이어스를 측정 및 교정하기 위한 조성물 및 방법
EP3640343B1 (en) 2012-10-01 2026-01-07 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
WO2015160439A2 (en) 2014-04-17 2015-10-22 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
JP6657105B2 (ja) 2013-11-06 2020-03-04 アメリカ合衆国 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法
ES2741740T3 (es) 2014-03-05 2020-02-12 Adaptive Biotechnologies Corp Métodos que usan moléculas sintéticas que contienen segmentos de nucleótidos aleatorios
BR112016020053A2 (pt) * 2014-03-27 2018-02-20 Genentech, Inc. métodos de previsão da reação de pacientes que sofrem de distúrbio inflamatório, de previsão da capacidade de reação de pacientes, de identificação de pacientes que sofrem de distúrbio inflamatório e de seu tratamento, usos de kit e kits
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
EP3715455A1 (en) 2014-10-29 2020-09-30 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
IL299075A (en) 2014-10-29 2023-02-01 Seagen Inc Dosage and administration of non-fucosylated anti-cd40 antibodies
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
WO2016086029A1 (en) 2014-11-25 2016-06-02 Adaptive Biotechnologies Corporation Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
ES3002665T3 (en) 2015-02-24 2025-03-07 Adaptive Biotechnologies Corp Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing
AU2016242967B2 (en) 2015-04-01 2021-07-01 Adaptive Biotechnologies Corp. Method of identifying human compatible T cell receptors specific for an antigenic target
US12366508B2 (en) 2015-07-30 2025-07-22 Qiagen Gmbh Method of preparing a frozen biological sample
DK3359688T3 (da) 2015-10-05 2021-08-23 Biogen Ma Inc Molekylære signaturer til anvendelse til diagnose og analyse af respons på behandling af autoimmune sygdomme
EP3458074B1 (en) * 2016-05-16 2024-04-17 Board of Regents of the University of Texas System COMPOSITIONS FOR THE DELIVERY OF tRNA AS NANOPARTICLES AND METHODS OF USE THEREWITH
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
KR102364599B1 (ko) * 2017-04-04 2022-02-21 에프. 호프만-라 로슈 아게 Cd40 및 fap에 특이적으로 결합할 수 있는 새로운 이중특이적 항원 결합 분자
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
US20240002941A1 (en) * 2020-12-02 2024-01-04 Albert Einstein College Of Medicine Method for predicting patient response to cd40-targeted therapies

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5182368A (en) 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
CA2179196A1 (en) 1993-12-23 1995-06-29 Richard J. Armitage Method of preventing or treating disease characterized by neoplastic cells expressing cd40
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US6248535B1 (en) 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
CA2402525A1 (en) 2000-03-31 2001-10-11 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
WO2002078766A2 (en) 2001-04-02 2002-10-10 Genentech, Inc. Combination therapy
JP4025881B2 (ja) 2001-04-27 2007-12-26 キリンファーマ株式会社 抗ｃｄ４０モノクローナル抗体
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
WO2004071572A2 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
US7767387B2 (en) * 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
EP1664762A4 (en) * 2003-09-03 2008-08-13 Us Gov Health & Human Serv METHOD OF IDENTIFYING AND DIAGNOSIS OF, AND VIEWING, SURVIVAL IN LYMPHOMA
ATE473016T1 (de) 2003-11-04 2010-07-15 Novartis Vaccines & Diagnostic Verfahren zur behandlung von krebs mit expression des cd40-antigens
EP1682177B8 (en) 2003-11-04 2010-09-01 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
EP2163650B1 (en) 2004-04-09 2015-08-05 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2006044294A2 (en) 2004-10-14 2006-04-27 Eli Lilly And Company Human protein c analogs
EP1894012A2 (en) 2005-05-18 2008-03-05 Novartis AG Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
ES2429564T3 (es) 2005-05-18 2013-11-15 Novartis Ag Procedimientos para el diagnóstico y tratamiento de enfermedades que tienen un componente autoinmune y/o inflamatorio
PL1885399T3 (pl) 2005-05-26 2011-04-29 Seattle Genetics Inc Humanizowane przeciwciała anty-CD40 i sposoby ich stosowania
MX2007015416A (es) 2005-06-08 2008-02-19 Millennium Pharm Inc Metodos para la identificacion, evaluacion y tratamiento de pacientes con terapia contra cancer.
EP1943523A2 (en) 2005-09-16 2008-07-16 Biovator Technologies AB In vitro assay for identification of allergenic proteins
DE102005052384B4 (de) 2005-10-31 2009-09-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens
US7527774B2 (en) 2005-12-22 2009-05-05 Basf Catalysts Llc Inlet metallic foam support coupled to precious metal catalyst for application on 4 stroke platforms
US20090075272A1 (en) 2006-01-20 2009-03-19 Hollmann C Annette Method to Identify CD40-Sensitive Cells Using Gene Expression
US9353415B2 (en) 2006-12-19 2016-05-31 Thomson Reuters (Scientific) Llc Methods for functional analysis of high-throughput experimental data and gene groups identified therefrom
WO2010121231A1 (en) 2009-04-18 2010-10-21 Genentech, Inc. Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies

Also Published As

Publication number Publication date
WO2009062125A1 (en) 2009-05-14
CN101910414A (zh) 2010-12-08
IL205391A0 (en) 2010-12-30
CA2704499A1 (en) 2009-05-14
EP2222875A1 (en) 2010-09-01
JP2014057588A (ja) 2014-04-03
EP2222875B1 (en) 2014-08-20
AU2008323701A1 (en) 2009-05-14
US9068230B2 (en) 2015-06-30
US20110104671A1 (en) 2011-05-05
JP2011504102A (ja) 2011-02-03
MX2010005080A (es) 2010-07-28
CA2704499C (en) 2020-03-10
IL205391A (en) 2015-08-31
KR20100095564A (ko) 2010-08-31
KR101620642B1 (ko) 2016-05-12
AU2008323701B2 (en) 2015-03-26
CN101910414B (zh) 2016-01-13
JP5730576B2 (ja) 2015-06-10

Similar Documents

Publication Publication Date Title
BRPI0820707A2 (pt) Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40
BRPI0818011A2 (pt) Método e dispositivo para associar objetos
DE602007004421D1 (de) Zellkulturvorrichtung
BRPI0910608A2 (pt) métodos e sistemas para avaliar resultados clínicos
BRPI0812509A2 (pt) Aparelho reformador e método
BRPI0817182A2 (pt) Método para purificar um anticorpo e composições
BRPI0807755A2 (pt) Sementes revestidas e métodos para fabricação de sementes revestidas.
FR2921407B1 (fr) Preleveur statique multi-niveaux
PT2853545T (pt) Anticorpo específico para ige
PT2328616E (pt) Composições e métodos para anticorpos dirigidos à proteína c5 do complemento
BRPI0813216A2 (pt) Inibidores de proteínas cinases e métodos para usá-los.
EP2217371A4 (en) CATALYSTS AND RELATED METHODS
CR10705A (es) Anticuerpos para linfotoxina-alfa
BRPI0718118A2 (pt) composições e métodos para ligação de sphingosine-1-fosfato
BRPI0818572A2 (pt) Depósito de material, e, dispositivo elétrico
BRPI0810525A2 (pt) Composições e métodos para a profilaxia e tratamento de dependência química
BRPI0821617A2 (pt) Dispositivos e métodos para reatores de fluxo contínuo alveolados
DK2013109T3 (da) Forbedret distributionsapparat
BRPI0920510A2 (pt) substrato com aderência para fezes e fluxo mesntrual
DE502007001209D1 (de) Wachszusammensetzung und deren Verwendung
DK2027150T3 (da) Allo-begrænsede peptid-specifikke t-celler
BRPI0914907B8 (pt) composição particulada para ração e ração
BRPI0718035A2 (pt) Método e disposição para fabricação de metanol
FI20075825A0 (fi) Jakelulaite
BRPI0815877A2 (pt) Dispositivo para aquecer um material metálico e método para aquecer um material metálico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements